Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine Inc. (MNMD) is a clinical-stage biotech company pioneering research into psychedelic-inspired therapies for mental health disorders. This dedicated news hub provides investors and researchers with timely updates on MNMD's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases detailing clinical trial progress, partnership announcements with leading research institutions, and analyses of the company's novel approaches to treating conditions like addiction and depression. Our curated collection ensures you stay informed about MNMD's work developing therapies that target neuroplasticity through compounds such as LSD-analogs and psilocybin derivatives.
Key updates include Phase 2 trial results, intellectual property developments, executive leadership changes, and presentations at major medical conferences. All content is sourced from verified channels to maintain compliance with financial disclosure standards.
Bookmark this page for streamlined access to MNMD's evolving story in psychedelic medicine. Check regularly for critical updates about FDA-regulated research programs and breakthrough therapy designation tracking within this emerging biopharmaceutical sector.
Mind Medicine (MNMD) has achieved a significant milestone in its clinical research by demonstrating the successful results of a double-blind trial on lysergide for treating Major Depressive Disorder (MDD). Conducted by researchers at University Hospital Basel, the study reported statistically significant improvements in MDD symptoms using a high-dose regimen of lysergide. Patients receiving 100 µg and 200 µg doses showed a mean score change of -12.9 compared to -3.6 in the lower dose group, with results maintained for up to 16 weeks post-treatment. The positive outcomes reinforce the drug’s potential in treating MDD and its relevance to MindMed’s MM-120 program focused on Generalized Anxiety Disorder (GAD). The findings were presented on April 14, 2023, in Basel, Switzerland, indicating promising future research and market implications for MindMed.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has appointed Mark R. Sullivan as Chief Legal Officer and Corporate Secretary, effective immediately. Sullivan brings extensive legal expertise in the life sciences sector, having previously served as General Counsel for Sesen Bio and MModal Inc. CEO Robert Barrow expressed optimism about Sullivan's contributions during a transformative phase for MindMed, which is advancing its clinical programs targeting brain health disorders. The company is focused on developing innovative treatments and improving patient outcomes. MindMed trades under the symbol MNMD on NASDAQ and MMED on the NEO Exchange.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced its financial results for the full year ended December 31, 2022, reporting cash and equivalents of $142.1 million. The company is focused on key Phase 2 clinical trials, including MM-120 for generalized anxiety disorder (GAD) and ADHD, with topline results expected in late 2023. Additionally, MindMed plans to initiate its first clinical trial of MM-402, targeting autism spectrum disorder (ASD), in 2023. The net loss for 2022 was $56.8 million, a decrease from $93 million in 2021. Management believes the current cash position will fund operations into the first half of 2025.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has announced its participation in three upcoming investor conferences. The events include the Cowen 43rd Annual Healthcare Conference on March 8, 2023, at 1:30 pm EST, the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 2:00 pm EST, and the 35th Annual Roth Conference on March 13, 2023, at 2:30 pm PST/5:30 pm EST. Webcasts for each conference will be available on MindMed's Investor Resources page for up to 90 days post-event. MindMed is focused on developing innovative treatments targeting brain health disorders, showcasing its commitment to improving patient outcomes.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) provided a corporate update and outlook for 2023, emphasizing significant upcoming milestones. The company anticipates key data readouts from its Phase 2b study of MM-120 for generalized anxiety disorder (GAD) and a Phase 2a trial for ADHD, both expected in late 2023. Additionally, MindMed plans to initiate its first clinical trial for MM-402, targeting autism spectrum disorder (ASD), later in the year. The company confirmed its strong cash position, expected to fund operations into the first half of 2025.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced its participation in the Jefferies London Healthcare Conference from November 15-17, 2022. The company's management team will present on November 16, 2022, at 3:50 p.m. GMT (10:50 a.m. EST). The event will include presentations and one-on-one meetings with investors. A webcast of the presentation will be available for replay for 90 days on MindMed's website. MindMed is focused on developing novel products for brain health disorders, aiming to improve patient outcomes.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported its Q3 2022 financial results, highlighting a net loss of $16.5 million, an improvement from $17.2 million in Q3 2021. The company has cash reserves of $154.5 million, sufficient to fund operations into 2025. MindMed has initiated a Phase 2b trial for MM-120 in patients with Generalized Anxiety Disorder, expecting topline results in late 2023. Additionally, it has made strides in clinical programs for MM-402 and reduced overall cash expenditures, raising $60 million to support ongoing developments.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) will hold an earnings call on November 10, 2022, at 8:30 a.m. EDT to discuss its financial results for the quarter ended September 30, 2022, and provide a business update. The call can be accessed by dialing (888) 999-3182 domestically or (848) 280-6330 internationally, using conference ID 8072033. The webcast will also be available on MindMed's Investor Resources webpage, archived for 30 days. The company focuses on developing innovative treatments for brain health disorders.
Mind Medicine (MindMed) announced its participation in the Cantor Fitzgerald Neurology & Psychiatry Conference from October 6-7, 2022, in San Francisco, CA. Members of the management team will be involved in panel presentations and one-on-one investor meetings. The panel titled 'Tripping our way to a new treatment paradigm for psychiatric disorders' is scheduled for October 6 at 12:10 p.m. PDT. MindMed aims to lead in developing innovative treatments for brain health disorders, focusing on drug candidates targeting serotonin, dopamine, and acetylcholine systems, trading under the symbol MNMD.
Mind Medicine (NASDAQ: MNMD) has launched a Phase 1 trial to compare the acute effects of R-MDMA, S-MDMA, and racemic MDMA in 24 healthy participants. The study, led by Prof. Dr. Matthias Liechti at University Hospital Basel, aims to investigate potential differences in subjective and physiological responses. Notably, preclinical studies suggest R-MDMA may have a better safety profile and enhanced prosocial effects compared to its counterparts. The trial will employ a randomized, placebo-controlled design, assessing various outcome measures.
FAQ
What is the current stock price of Mind Medicine (MNMD)?
What is the market cap of Mind Medicine (MNMD)?
